RCKT ▲ +1.6% - Rocket Pharmaceuticals, Inc.
$RCKT Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
07-OCT-2026 09:36 AM ET
Share this post
More filings for $RCKT
RCKT ▲ +1.6% - Rocket Pharmaceuticals, Inc.Oct 7, 2026RCKT ▼ -3.4% - Rocket Pharmaceuticals, Inc.Oct 6, 2026RCKT ▲ +4.1% - Rocket Pharmaceuticals, Inc.Sep 15, 2026RCKT ▲ +0.6% - Rocket Pharmaceuticals, Inc.Sep 15, 2026RCKT ▼ -0.5% - Rocket Pharmaceuticals, Inc.Sep 3, 2026$RCKT SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 31, 2026
View full $RCKT filing history →💬 Comments
Loading comments…
Leave a comment